155 related articles for article (PubMed ID: 17060982)
21. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts.
Ye L; He J; Hu Z; Dong Q; Wang H; Fu F; Tian J
Food Chem Toxicol; 2013 Feb; 52():200-6. PubMed ID: 23149094
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel.
Wada M; Jinno H; Ueda M; Ikeda T; Kitajima M; Konno T; Watanabe J; Ishihara K
Anticancer Res; 2007; 27(3B):1431-5. PubMed ID: 17595758
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
24. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
25. [Solubilizing and sustained-releasing abilities and safety preliminary evaluation for paclitaxel based on N-octyl-O, N-carboxymethyl chitosan polymeric micelles].
Huo MR; Zhang Y; Zhou JP; Lü L; Liu H; Liu FJ
Yao Xue Xue Bao; 2008 Aug; 43(8):855-61. PubMed ID: 18956780
[TBL] [Abstract][Full Text] [Related]
26. Liposomal paclitaxel formulations.
Koudelka S; Turánek J
J Control Release; 2012 Nov; 163(3):322-34. PubMed ID: 22989535
[TBL] [Abstract][Full Text] [Related]
27. Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies.
Dhanikula RS; Dhanikula AB; Panchagnula R
Pharmazie; 2008 Jun; 63(6):439-45. PubMed ID: 18604987
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes.
Jiménez-López J; Bravo-Caparrós I; Cabeza L; Nieto FR; Ortiz R; Perazzoli G; Fernández-Segura E; Cañizares FJ; Baeyens JM; Melguizo C; Prados J
Biomed Pharmacother; 2021 Jan; 133():111059. PubMed ID: 33378963
[TBL] [Abstract][Full Text] [Related]
29. Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice.
Rafferty P; Egenolf D; Brosnan K; Makropoulos D; Jordan J; Meshaw K; Walker M; Volk A; Bugelski PJ
J Immunotoxicol; 2012; 9(1):43-55. PubMed ID: 22299716
[TBL] [Abstract][Full Text] [Related]
30. [Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice].
Huo MR; Zhou JP; Wei Y; Lü L
Yao Xue Xue Bao; 2006 Sep; 41(9):867-72. PubMed ID: 17111835
[TBL] [Abstract][Full Text] [Related]
31. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
32. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
33. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
34. Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis.
Zhang H; Hu H; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Nanoscale; 2015 Jun; 7(24):10790-800. PubMed ID: 26038337
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
Stathopoulos GP; Dimitroulis J; Toubis M; Katis C; Karaindros D; Stathopoulos J; Koutandos J
Lung Cancer; 2007 Jul; 57(1):66-71. PubMed ID: 17382431
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of liposome encapsulation on paclitaxel developmental toxicity in the rat.
Scialli AR; Waterhouse TB; Desesso JM; Rahman A; Goeringer GC
Teratology; 1997 Nov; 56(5):305-10. PubMed ID: 9451754
[TBL] [Abstract][Full Text] [Related]
38. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
Yu YH; Kim E; Park DE; Shim G; Lee S; Kim YB; Kim CW; Oh YK
Eur J Pharm Biopharm; 2012 Feb; 80(2):268-73. PubMed ID: 22108492
[TBL] [Abstract][Full Text] [Related]
39. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and toxicological studies of cremophor EL free alternative paclitaxel formulation.
Utreja P; Jain S; Yadav S; Khandhuja KL; Tiwary AK
Curr Drug Saf; 2011 Nov; 6(5):329-38. PubMed ID: 22424541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
